August 23, 2007 - Cannasat Therapeutics Inc. ("Cannasat") (TSX-V: CTH), announced that Health Canada has approved Cannasat’s clinical trial application for a Phase 1 clinical study with its lead product, CAT 310, its first cannabinoid based product that is designed to help manage neuropathic pain and other disorders... Neuropathic pain can be caused by many common diseases such as diabetes... Cannasat Therapeutics' Press Release.
Friday, August 24, 2007
Cannasat Therapeutics, Commence Phase 1 Study of CAT 310, Potential Treatment for Neuropathic Pain
August 23, 2007 - Cannasat Therapeutics Inc. ("Cannasat") (TSX-V: CTH), announced that Health Canada has approved Cannasat’s clinical trial application for a Phase 1 clinical study with its lead product, CAT 310, its first cannabinoid based product that is designed to help manage neuropathic pain and other disorders... Neuropathic pain can be caused by many common diseases such as diabetes... Cannasat Therapeutics' Press Release.
